updat beckman bnp litig
decemb life scienc tool diagnost colleagu meehan publish note regard legal disput
beckman
link note corp buy dip bnp legal risk fulli reflect lower pt
friday afternoon et comment rule san diego superior court bnp litig ith beckman
coulter court intend rule provis restrict beckman manufactur sell anoth bnp assay void
matter law essenc pend appeal clear path beckman develop market competitor bnp test
platform quidel stock end day dow vs dow point manag maintain
beckman case meritless host confer call monday et discuss litig given magnitud
friday stock reaction believ risk relat bnp litig fulli reflect valuat recommend
buy dip option around ultim bnp outcom legal appeal august trial asset sale well
action adjust forecast given uncertainti around impact friday announc appeal
unsuccess could still take beckman coulter year bring competit bnp test market hich time compani
reliant suppli agreement ith offer critic test custom clear point whether would
make adjust forecast regardless friday announc said reduc pt
given weaker visibl durabl bnp revenu cash flow estim bnp cash flow orth
per share reduc pt due near-term cash flow potenti asset sale
observ announc obvious surpris us market competitor confer
quidel comment highli confid motion ould dismiss opinion stock reaction friday
afternoon impli compani ill lose bnp revenu stream estim almost market valu destroy
relat announc hich essenti valu asset multipl potenti avenu take
includ legal action appeal pursu matter august trial bnp asset sale beckman coulter
julian mitchel herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill directli
indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog overw eight rate target price predic upon follow ing methodolog dcf
tba
risk may imped achiev barclay research valuat price revenu
gener life scienc diagnost end market uncertainti surround regul could lead paus custom
demand come year
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog pt repres cash ep forecast given forecast grow th around
per year impli bnp orth ep pt also repres pro-forma cash ep
forecast assum busi goe aw ay given forecast grow th around per year also impli pro-forma
risk may imped achiev barclay research valuat price acquisit triage/bnp
carri merger relat risk integr sell disrupt risk market rapid flu test could move
molecular though believ orkflow issu continu favor immunoassay solut savanna mdx launch allow
particip grow th market move direct exhibit signific season volatil relat flu
season hich impact pace revenu grow th profit cash flow rel low er barrier entri
market compar area diagnost
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
